Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.08)
# 4,417
Out of 5,044 analysts
4
Total ratings
25%
Success rate
-37.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $29.76 | +205.78% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $3.40 | +252.94% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $87.03 | +28.69% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $29.76
Upside: +205.78%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $3.40
Upside: +252.94%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $87.03
Upside: +28.69%